Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
Bürki
Franck
F
Badie
Kattalin
K
Bartoli
Philippe
P
Bernard
Pascale
P
Montastruc
Jean Louis
JL
Bagheri
Haleh
H
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004317:Doxorubicin